{"id":"period-b","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL1161637","moleculeType":"Small molecule","molecularWeight":"191.91"},"_dailymed":{"setId":"40d2ae73-82cf-3fa1-e063-6394a90a9ea2","title":"PERIOD PILLS BY BIIKAY (ACETAMINOPHEN, IBUPROFEN) TABLET [KAI SQUARED]"},"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Period B works by activating melatonin receptors in the brain, which helps to regulate the body's natural sleep-wake cycle. This can help improve sleep quality and duration in individuals with insomnia. By targeting the melatonin receptor, Period B can help to reduce symptoms of insomnia and improve overall sleep health.","oneSentence":"Period B is a melatonin receptor agonist that helps regulate sleep-wake cycles.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:51:47.425Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Insomnia"}]},"trialDetails":[{"nctId":"NCT04759586","phase":"PHASE3","title":"Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-05","conditions":"Primary Mediastinal Large B-Cell Lymphoma","enrollment":244},{"nctId":"NCT06356610","phase":"NA","title":"Pharmacokinetic and Subjective Effects of Heated Tobacco Products","status":"COMPLETED","sponsor":"Altria Client Services LLC","startDate":"2024-02-06","conditions":"Tobacco Use","enrollment":80},{"nctId":"NCT07494539","phase":"NA","title":"Induction of Labor by Cervical Ripening and Transcutaneous Electrical Nerve Stimulation (TENS)","status":"NOT_YET_RECRUITING","sponsor":"HOT Noémie","startDate":"2026-04-01","conditions":"Labor Pain, Induction of Labor","enrollment":132},{"nctId":"NCT06134440","phase":"NA","title":"ImmunoNutrition and Colorectal Adenocarcinoma Surgery - INCAS Study","status":"TERMINATED","sponsor":"Istituto Oncologico Veneto IRCCS","startDate":"2023-11-21","conditions":"Colorectal Adenocarcinoma","enrollment":71},{"nctId":"NCT07495150","phase":"NA","title":"Intracalvariosseous Plus Intravenous Antibiotics for Moderate-to-Severe Bacterial Meningitis","status":"NOT_YET_RECRUITING","sponsor":"yilong Wang","startDate":"2026-04-01","conditions":"Blood-Brain Barrier, Bacterial Meningitis","enrollment":86},{"nctId":"NCT07494084","phase":"PHASE4","title":"Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance","status":"NOT_YET_RECRUITING","sponsor":"Washington State University","startDate":"2026-05-01","conditions":"Shift Work Schedule, Circadian Rhythm, Insulin Resistance","enrollment":24},{"nctId":"NCT04301076","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment (\"EPOCH\") for Adult T-Cell Leukemia-Lymphoma (ATLL)","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-08-31","conditions":"Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma, Chronic Adult T-Cell Leukemia/Lymphoma","enrollment":30},{"nctId":"NCT06899061","phase":"PHASE1","title":"Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-25","conditions":"Advanced Solid Malignancies","enrollment":41},{"nctId":"NCT06273644","phase":"NA","title":"Clinical Research on Acute Intermittent Porphyria and the Use of Carbohydrate-Rich Diet as a Treatment","status":"RECRUITING","sponsor":"Nordlandssykehuset HF","startDate":"2024-01-27","conditions":"Porphyria, Acute Intermittent","enrollment":50},{"nctId":"NCT05531565","phase":"PHASE2, PHASE3","title":"A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus","status":"RECRUITING","sponsor":"Biogen","startDate":"2022-09-13","conditions":"Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus","enrollment":450},{"nctId":"NCT07497568","phase":"NA","title":"Effect of Local Application of 1% Metformin Gel on Implant Stability and Peri-implant Bone Density: A Randomized Controlled Study","status":"RECRUITING","sponsor":"University of Baghdad","startDate":"2025-11-01","conditions":"Dental Implant, Stability","enrollment":34},{"nctId":"NCT04123795","phase":"PHASE3","title":"A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"UCB Biopharma SRL","startDate":"2020-01-21","conditions":"Moderate Chronic Plaque Psoriasis, Severe Chronic Plaque Psoriasis, Mixed Guttate/Plaque Psoriasis","enrollment":49},{"nctId":"NCT07045038","phase":"NA","title":"Blood Flow Restricted Resistance Exercises Versus Low Level Laser on Cardiac Functions in Patients With Chronic Heart Failure","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cairo University","startDate":"2025-01-20","conditions":"Heart Failure NYHA Class II","enrollment":60},{"nctId":"NCT03984448","phase":"PHASE2, PHASE3","title":"Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-10-22","conditions":"Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double-Expressor Lymphoma","enrollment":363},{"nctId":"NCT03569891","phase":"PHASE3","title":"HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2018-06-27","conditions":"Hemophilia B","enrollment":67},{"nctId":"NCT07375992","phase":"NA","title":"Music Therapy in Newly Diagnosed Glioblastoma After Chemoradiation Therapy (MELODY-GBM)","status":"NOT_YET_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2026-04","conditions":"Feasibility Studies","enrollment":35},{"nctId":"NCT07495514","phase":"PHASE1","title":"A Study to Evaluate the Effect of Food on the Pharmacokinetic Characteristics and Safety Profile of AD-117 in Healthy Adult Volunteers","status":"ENROLLING_BY_INVITATION","sponsor":"Addpharma Inc.","startDate":"2026-02","conditions":"Mixed Dyslipidemia, Food Effect Study of AD-117","enrollment":60},{"nctId":"NCT04886999","phase":"PHASE3","title":"Study in Adult Patients With Moderate to Severe Asthma","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2022-02-24","conditions":"Asthma","enrollment":78},{"nctId":"NCT07285460","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-12-18","conditions":"Hemophilia","enrollment":85},{"nctId":"NCT07497594","phase":"NA","title":"ImPrEP LEN Brasil: Twice-Yearly Lenacapavir for HIV Prevention","status":"RECRUITING","sponsor":"Oswaldo Cruz Foundation","startDate":"2026-02-03","conditions":"Contact With or Exposure to Human Immunodeficiency Virus","enrollment":1500},{"nctId":"NCT06154447","phase":"PHASE1","title":"Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis","status":"RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2023-12-12","conditions":"Cystic Fibrosis","enrollment":255},{"nctId":"NCT05546996","phase":"NA","title":"EVD Drainage Data and Intracranial Pressure (ICP) Measurements","status":"RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2023-07-11","conditions":"Hydrocephalus","enrollment":24},{"nctId":"NCT07492355","phase":"PHASE1","title":"TP-3654 Food Effect Study","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2024-03-04","conditions":"Myelofibroses","enrollment":24},{"nctId":"NCT06834035","phase":"PHASE1, PHASE2","title":"Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa","status":"RECRUITING","sponsor":"M. Peter Marinkovich","startDate":"2025-08-04","conditions":"Epidermolysis Bullosa, Epidermolysis Bullosa Acquisita, Dystrophic Epidermolysis Bullosa","enrollment":8},{"nctId":"NCT07093398","phase":"PHASE1","title":"A Phase 1 Study to Assess Food Effect on the Pharmacokinetics of D3S-001 in Healthy Adult Participants","status":"COMPLETED","sponsor":"D3 Bio (Wuxi) Co., Ltd","startDate":"2025-07-11","conditions":"Healthy Adult Volunteers","enrollment":26},{"nctId":"NCT05701657","phase":"NA","title":"Nutrition for Precision Health, Powered by the All of Us","status":"RECRUITING","sponsor":"RTI International","startDate":"2023-04-14","conditions":"Nutrition, Health, Dietary Habits","enrollment":8000},{"nctId":"NCT07202481","phase":"NA","title":"Chronic Ingestion of Fructooligosaccharide and Psyllium on Intestinal Transit in Women With Functional Constipation: A Randomized Crossover Trial","status":"RECRUITING","sponsor":"Federal University of Minas Gerais","startDate":"2026-03-14","conditions":"Constipation - Functional","enrollment":25},{"nctId":"NCT07270861","phase":"","title":"Real-world Outcomes of Peripheral T-cell Lymphoma: A Multicenter Retrospective and Prospective Cohort Study","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-11-15","conditions":"Peripheral T-Cell Lymphoma","enrollment":3000},{"nctId":"NCT07476079","phase":"NA","title":"Optimization and Validation of Electric Acoustic Stimulation (EAS) Mapping as a Function of Residual Hearing After CI-Implantation","status":"NOT_YET_RECRUITING","sponsor":"Luzerner Kantonsspital","startDate":"2026-04-20","conditions":"Fitting Methods by EAS Patients","enrollment":12},{"nctId":"NCT05910528","phase":"PHASE2","title":"Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-07-24","conditions":"Crohns Disease","enrollment":21},{"nctId":"NCT07490301","phase":"PHASE2, PHASE3","title":"A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"AbbVie","startDate":"2026-06-03","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma, PDAC","enrollment":900},{"nctId":"NCT06618976","phase":"PHASE4","title":"Antithrombotic Activities of Sotagliflozin vs. Empagliflozin","status":"ACTIVE_NOT_RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2025-02-25","conditions":"Thrombosis","enrollment":17},{"nctId":"NCT04082429","phase":"PHASE3","title":"Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2019-11-13","conditions":"Haemophilia A Without Inhibitors, Haemophilia B Without Inhibitors","enrollment":156},{"nctId":"NCT06609226","phase":"PHASE3","title":"A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-01-10","conditions":"Sickle Cell Disease, Thalassemia","enrollment":480},{"nctId":"NCT07224100","phase":"PHASE2","title":"Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-15","conditions":"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1, Lymphoblastic Lymphoma","enrollment":33},{"nctId":"NCT04384484","phase":"PHASE3","title":"Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"ADC Therapeutics S.A.","startDate":"2020-09-16","conditions":"Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma","enrollment":440},{"nctId":"NCT06430385","phase":"PHASE1, PHASE2","title":"ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS)","status":"RECRUITING","sponsor":"Ionis Pharmaceuticals, Inc.","startDate":"2024-10-21","conditions":"Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome","enrollment":48},{"nctId":"NCT04083781","phase":"PHASE3","title":"Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With Inhibitors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2019-10-21","conditions":"Haemophilia A With Inhibitors, Haemophilia B With Inhibitors","enrollment":134},{"nctId":"NCT07101926","phase":"","title":"Monitoring of Anti-TFPI in Hemophilia","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2025-10-23","conditions":"Hemophilia, Rebalancing Agents, Prophylaxis","enrollment":11},{"nctId":"NCT06983665","phase":"NA","title":"Human Bioequivalence Study of Liposomal Amphotericin B for Injection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Huiyu Pharmaceutical Co., Ltd","startDate":"2025-05-25","conditions":"Invasive Fungal Infections, Neutropenic Fever, Visceral Leishmaniasis","enrollment":42},{"nctId":"NCT06894004","phase":"NA","title":"Mechanism of Ketogenic Diet-Induced Hypercholesterolemia","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2025-02-24","conditions":"Hypercholesterolemia and Hyperlipidemia","enrollment":100},{"nctId":"NCT07487740","phase":"PHASE1","title":"A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants","status":"RECRUITING","sponsor":"Trevi Therapeutics","startDate":"2026-02-27","conditions":"Healthy Participants","enrollment":60},{"nctId":"NCT06343584","phase":"","title":"Are Personal Smartphones Hurting Work-Life Balance for Nurse Managers?","status":"COMPLETED","sponsor":"Methodist Health System","startDate":"2021-07-01","conditions":"Burnout","enrollment":6},{"nctId":"NCT00338377","phase":"PHASE2","title":"Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-02-01","conditions":"Melanoma","enrollment":1230},{"nctId":"NCT07018700","phase":"PHASE3","title":"A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine","status":"RECRUITING","sponsor":"Merz Therapeutics GmbH","startDate":"2025-08-21","conditions":"Episodic Migraine","enrollment":990},{"nctId":"NCT07486453","phase":"PHASE1","title":"Bioequivalence Study of Sacubitril Alisartan Amlodipine Tablets","status":"NOT_YET_RECRUITING","sponsor":"Shenzhen Salubris Pharmaceuticals Co., Ltd.","startDate":"2026-03-09","conditions":"Primary Hypertension","enrollment":60},{"nctId":"NCT07018713","phase":"PHASE3","title":"A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine","status":"RECRUITING","sponsor":"Merz Therapeutics GmbH","startDate":"2025-08-21","conditions":"Chronic Migraine","enrollment":780},{"nctId":"NCT07449390","phase":"PHASE1","title":"Drug-drug Interaction Trial of AP31969 and Carbamazepine or Itraconazole","status":"NOT_YET_RECRUITING","sponsor":"Acesion Pharma","startDate":"2026-04-22","conditions":"Healthy Participants","enrollment":28},{"nctId":"NCT06831955","phase":"PHASE2","title":"LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2026-02-01","conditions":"Triple Negative Breast Cancer (TNBC), Early Setting","enrollment":356},{"nctId":"NCT07316010","phase":"PHASE2","title":"Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-06-01","conditions":"Large B-cell Lymphoma","enrollment":10},{"nctId":"NCT06468228","phase":"PHASE3","title":"A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa","status":"RECRUITING","sponsor":"AbbVie","startDate":"2024-06-27","conditions":"Hidradenitis Suppurativa","enrollment":1280},{"nctId":"NCT05711394","phase":"PHASE3","title":"A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine","status":"RECRUITING","sponsor":"AbbVie","startDate":"2023-05-01","conditions":"Episodic Migraine","enrollment":450},{"nctId":"NCT06226883","phase":"PHASE2","title":"A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease","status":"RECRUITING","sponsor":"Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)","startDate":"2024-07-18","conditions":"Inflammatory Bowel Diseases, Crohn's Disease","enrollment":385},{"nctId":"NCT06152185","phase":"NA","title":"Mindfulness App Training for Cardiovascular Health","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pittsburgh","startDate":"2024-02-06","conditions":"Cardiovascular Diseases, Mindfulness","enrollment":106},{"nctId":"NCT06430957","phase":"","title":"OSA Risk Level in Dental Patients and Correlation With Complications After General Anesthesia","status":"RECRUITING","sponsor":"Kırıkkale University","startDate":"2024-06-28","conditions":"Obstructive Sleep Apnea Risk Management, Postoperative Complications, Dental Caries Under General Anesthesia","enrollment":240},{"nctId":"NCT06898450","phase":"PHASE1, PHASE2","title":"A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.","status":"RECRUITING","sponsor":"Nimbus Wadjet, Inc.","startDate":"2025-03-31","conditions":"Advanced Solid Tumors Cancer, MSI-H Cancer","enrollment":134},{"nctId":"NCT07483632","phase":"PHASE3","title":"A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)","status":"NOT_YET_RECRUITING","sponsor":"Biogen","startDate":"2026-11-16","conditions":"Relapsing Forms of Multiple Sclerosis","enrollment":185},{"nctId":"NCT06036836","phase":"PHASE2","title":"Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-09-29","conditions":"Solid Tumor, Cutaneous Squamous Cell Carcinoma, Endometrial Cancer","enrollment":163},{"nctId":"NCT07398677","phase":"NA","title":"SchoolCare: A Social Intervention Introducing Telepresence Robots and School Navigation to Reduce School Fragmentation for Children Undergoing Cancer Treatment","status":"RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2026-02-20","conditions":"School Attendance, Academic Level, Childhood Cancer Survivors","enrollment":128},{"nctId":"NCT07159841","phase":"PHASE2, PHASE3","title":"A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)","status":"RECRUITING","sponsor":"Crinetics Pharmaceuticals Inc.","startDate":"2026-01-22","conditions":"Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia","enrollment":153},{"nctId":"NCT06053749","phase":"","title":"An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2024-03-20","conditions":"Multiple Sclerosis (MS)","enrollment":4},{"nctId":"NCT07226362","phase":"PHASE1","title":"A Study Evaluating the Safety, Tolerability and Pharmacokinetics of ASY202 in Healthy Adults","status":"COMPLETED","sponsor":"Aspeya Switzerland SA","startDate":"2025-06-09","conditions":"Safety, and Tolerability","enrollment":44},{"nctId":"NCT04910568","phase":"PHASE1","title":"A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2021-07-26","conditions":"Multiple Myeloma","enrollment":126},{"nctId":"NCT04538664","phase":"PHASE3","title":"A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2020-10-13","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":308},{"nctId":"NCT07482371","phase":"NA","title":"Comparative Effects of Scooping Mobilization and Dynamic Cupping Therapy on Elbow Stiffness","status":"RECRUITING","sponsor":"Riphah International University","startDate":"2025-10-22","conditions":"Children, Adults","enrollment":28},{"nctId":"NCT06998524","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-06-27","conditions":"Von Willebrand Disease, Type 3","enrollment":75},{"nctId":"NCT07480434","phase":"PHASE1","title":"Role of Enteral Lactoferrin as an Adjuvant for Prevention of Sepsis Among Preterm Neonates","status":"COMPLETED","sponsor":"Zartash Sial Paeds Med","startDate":"2024-10-01","conditions":"Sepsis","enrollment":180},{"nctId":"NCT05995353","phase":"PHASE3","title":"A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease","status":"RECRUITING","sponsor":"AbbVie","startDate":"2023-12-11","conditions":"Crohn's Disease","enrollment":110},{"nctId":"NCT06988423","phase":"PHASE1","title":"Evaluation of the Potential Impact of a High-fat Meal on the Pharmacokinetics of CRS3123 in Healthy Adult Participants","status":"COMPLETED","sponsor":"Crestone, Inc","startDate":"2025-04-21","conditions":"Food Effect in Healthy Participants","enrollment":17},{"nctId":"NCT06980480","phase":"PHASE3","title":"A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma","status":"RECRUITING","sponsor":"Takeda","startDate":"2026-01-14","conditions":"Multiple Myeloma, Secondary Immunodeficiency","enrollment":183},{"nctId":"NCT06833957","phase":"","title":"Preparing for Maternal GBS Vaccine Trials in Africa","status":"RECRUITING","sponsor":"Barcelona Institute for Global Health","startDate":"2025-03-01","conditions":"Group B Streptococcus, Invasive Bacterial Diseases (IBD), Maternal Immunization","enrollment":18100},{"nctId":"NCT07476157","phase":"PHASE1","title":"A Study to Evaluate the Safety and Pharmacokinetics of AD-118 and AD-1181 in Healthy Adult Subjects","status":"NOT_YET_RECRUITING","sponsor":"Addpharma Inc.","startDate":"2026-04","conditions":"Chronic Heart Failure","enrollment":70},{"nctId":"NCT07005193","phase":"NA","title":"Effects of LPG and Ventilation Interventions on Reducing HAP and Improving Cardiopulmonary Health","status":"RECRUITING","sponsor":"Huazhong University of Science and Technology","startDate":"2025-07-01","conditions":"Cardiopulmonary Function, Environmental Exposures","enrollment":1200},{"nctId":"NCT04870203","phase":"PHASE3","title":"Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Bordeaux","startDate":"2021-07-15","conditions":"Rheumatoid Arthritis","enrollment":160},{"nctId":"NCT07470307","phase":"NA","title":"Dynamic Lumbar Strengthening Exercises Versus Pilates, Combined With Myofascial Release in Non Specific Chronic Low Back Pain","status":"RECRUITING","sponsor":"Maheen Rauf","startDate":"2026-03-19","conditions":"Non-specific Chronic Low Back Pain","enrollment":60},{"nctId":"NCT07422298","phase":"PHASE1","title":"A Study to Evaluate the Effect of BMS-986278 on Cardiac Repolarization in Healthy Participants","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2026-02-19","conditions":"Healthy Volunteers","enrollment":32},{"nctId":"NCT07476378","phase":"NA","title":"A Study to Evaluate MTM-H-001 Injection in Adult Participants With Relapsed or Refractory B-cell Malignancies","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-03","conditions":"Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Follicular, Lymphoma, Mantle-Cell","enrollment":69},{"nctId":"NCT02467270","phase":"PHASE2","title":"Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-07-13","conditions":"Myeloid Leukemia, Chronic, Chronic Phase","enrollment":283},{"nctId":"NCT07133555","phase":"NA","title":"Safe Spaces 4 Sexual Health","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2025-08-10","conditions":"HIV Counseling and Testing, HIV Risk Behavior, HIV Prevention","enrollment":100},{"nctId":"NCT07478627","phase":"NA","title":"Comparison of Rehabilitation Exercise Protocol (5R) and Swiss Ball Training for Postpartum Pelvic Floor Muscle Dysfunction","status":"RECRUITING","sponsor":"Rafia Abrar","startDate":"2026-03-23","conditions":"Pelvic Floor Muscle Dysfunction","enrollment":88},{"nctId":"NCT07157254","phase":"PHASE2","title":"A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)","status":"RECRUITING","sponsor":"Ultragenyx Pharmaceutical Inc","startDate":"2025-10-13","conditions":"Angelman Syndrome","enrollment":60},{"nctId":"NCT03842982","phase":"PHASE3","title":"Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Oscar Lambret","startDate":"2019-05-03","conditions":"Ovary Neoplasms, Ovarian Cancer, Ovarian Carcinoma","enrollment":362},{"nctId":"NCT06744647","phase":"PHASE2","title":"Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation","status":"RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2025-03-07","conditions":"Antibody-Mediated Rejection, Kidney Transplantation, Biopsy-proven Histologic Scores","enrollment":45},{"nctId":"NCT07276399","phase":"PHASE3","title":"A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2025-12-03","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":500},{"nctId":"NCT07470125","phase":"PHASE1","title":"Bioequivalence (BE) Study Between YHP2511 and YHP2511A in Healthy Volunteers","status":"NOT_YET_RECRUITING","sponsor":"Yuhan Corporation","startDate":"2026-06-23","conditions":"Healthy Subjects","enrollment":60},{"nctId":"NCT06319820","phase":"PHASE3","title":"A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-04-18","conditions":"Non-Muscle Invasive Bladder Neoplasms","enrollment":641},{"nctId":"NCT04892173","phase":"PHASE3","title":"JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC","status":"RECRUITING","sponsor":"Johnson & Johnson Enterprise Innovation Inc.","startDate":"2021-12-10","conditions":"Locally Advanced Head and Neck Squamous Cell Carcinoma, Aged","enrollment":500},{"nctId":"NCT06738368","phase":"PHASE2","title":"Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-01","conditions":"B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia","enrollment":30},{"nctId":"NCT06772532","phase":"PHASE1","title":"A Study in Healthy People to Compare How 3 Different Formulations of Survodutide Are Taken up in the Body","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2025-02-10","conditions":"Healthy","enrollment":30},{"nctId":"NCT06785012","phase":"PHASE2","title":"A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-12-26","conditions":"Depressive Disorder, Major","enrollment":124},{"nctId":"NCT05772546","phase":"PHASE2","title":"Avatrombopag vs. Placebo for CIT in GI Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hanny Al-Samkari, MD","startDate":"2023-11-01","conditions":"Gastrointestinal Cancer, Gastrointestinal Neoplasms, Chemotherapy-Induced Thrombocytopenia","enrollment":60},{"nctId":"NCT06510309","phase":"PHASE2","title":"Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma","status":"RECRUITING","sponsor":"Gottfried von Keudell, MD PhD","startDate":"2026-02-11","conditions":"Lymphoma, Marginal Zone Lymphoma, MZL","enrollment":33},{"nctId":"NCT05453500","phase":"PHASE2","title":"Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"University of Washington","startDate":"2023-03-27","conditions":"B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative","enrollment":30},{"nctId":"NCT06038539","phase":"PHASE3","title":"Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer","status":"TERMINATED","sponsor":"Biocon Biologics UK Ltd","startDate":"2025-01-06","conditions":"HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients","enrollment":55},{"nctId":"NCT04577833","phase":"PHASE1","title":"A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2020-11-13","conditions":"Prostatic Neoplasms","enrollment":136},{"nctId":"NCT07345130","phase":"PHASE1","title":"A Bioequivalence Study of Advil Tablet (Mini) (Ibuprofen 200 mg) Versus Advil Tablet (Ibuprofen 200 mg) in Healthy Adult Subjects Under Fasted Conditions and Bioavailability Assessment of Advil Tablet (Mini) Under Fed Conditions","status":"COMPLETED","sponsor":"HALEON","startDate":"2025-12-17","conditions":"Bioequivalence, Bioavailability","enrollment":50},{"nctId":"NCT07455825","phase":"PHASE1","title":"A Study to Investigate the Pharmacokinetics of Different Formulations and Safety of AZD5004 in Healthy Participants Aged 18 to 55 Years","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-03-05","conditions":"Healthy Participants","enrollment":64},{"nctId":"NCT07433569","phase":"PHASE1","title":"A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-03-05","conditions":"Asthma","enrollment":12},{"nctId":"NCT05936567","phase":"PHASE2","title":"Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2023-07-31","conditions":"Urticaria, Chronic Spontaneous Urticaria, Chronic Idiopathic Urticaria","enrollment":136},{"nctId":"NCT06799000","phase":"PHASE3","title":"A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-01-31","conditions":"Hidradenitis Suppurativa","enrollment":555}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":850,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Period B","genericName":"Period B","companyName":"Apnimed","companyId":"apnimed","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Period B is a melatonin receptor agonist that helps regulate sleep-wake cycles. Used for Insomnia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}